These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. Lonskaya I; Hebron ML; Desforges NM; Schachter JB; Moussa CE J Mol Med (Berl); 2014 Apr; 92(4):373-86. PubMed ID: 24337465 [TBL] [Abstract][Full Text] [Related]
5. Znf179 E3 ligase-mediated TDP-43 polyubiquitination is involved in TDP-43- ubiquitinated inclusions (UBI) (+)-related neurodegenerative pathology. Lee YC; Huang WC; Lin JH; Kao TJ; Lin HC; Lee KH; Lin HC; Shen CJ; Chang WC; Huang CC J Biomed Sci; 2018 Nov; 25(1):76. PubMed ID: 30404641 [TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibition reverses TDP-43 effects on synaptic protein expression, astrocytic function and amino acid dis-homeostasis. Heyburn L; Hebron ML; Smith J; Winston C; Bechara J; Li Z; Lonskaya I; Burns MP; Harris BT; Moussa CE J Neurochem; 2016 Nov; 139(4):610-623. PubMed ID: 27507246 [TBL] [Abstract][Full Text] [Related]
7. Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer's disease models. Lonskaya I; Hebron ML; Selby ST; Turner RS; Moussa CE Neuroscience; 2015 Sep; 304():316-27. PubMed ID: 26235435 [TBL] [Abstract][Full Text] [Related]
8. Distinct multilevel misregulations of Parkin and PINK1 revealed in cell and animal models of TDP-43 proteinopathy. Sun X; Duan Y; Qin C; Li JC; Duan G; Deng X; Ni J; Cao X; Xiang K; Tian K; Chen CH; Li A; Fang Y Cell Death Dis; 2018 Sep; 9(10):953. PubMed ID: 30237395 [TBL] [Abstract][Full Text] [Related]
9. Parkin reverses TDP-43-induced cell death and failure of amino acid homeostasis. Hebron M; Chen W; Miessau MJ; Lonskaya I; Moussa CE J Neurochem; 2014 Apr; 129(2):350-61. PubMed ID: 24298989 [TBL] [Abstract][Full Text] [Related]
10. Nilotinib: A Tyrosine Kinase Inhibitor Mediates Resistance to Intracellular Mycobacterium Via Regulating Autophagy. Hussain T; Zhao D; Shah SZA; Sabir N; Wang J; Liao Y; Song Y; Dong H; Hussain Mangi M; Ni J; Yang L; Zhou X Cells; 2019 May; 8(5):. PubMed ID: 31130711 [TBL] [Abstract][Full Text] [Related]
11. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662 [TBL] [Abstract][Full Text] [Related]
12. Praja1 RING-finger E3 ubiquitin ligase suppresses neuronal cytoplasmic TDP-43 aggregate formation. Watabe K; Kato Y; Sakuma M; Murata M; Niida-Kawaguchi M; Takemura T; Hanagata N; Tada M; Kakita A; Shibata N Neuropathology; 2020 Dec; 40(6):570-586. PubMed ID: 32686212 [TBL] [Abstract][Full Text] [Related]
13. The ubiquitin E3 ligase parkin regulates the proapoptotic function of Bax. Johnson BN; Berger AK; Cortese GP; Lavoie MJ Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6283-8. PubMed ID: 22460798 [TBL] [Abstract][Full Text] [Related]
14. STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's disease. Kurup PK; Xu J; Videira RA; Ononenyi C; Baltazar G; Lombroso PJ; Nairn AC Proc Natl Acad Sci U S A; 2015 Jan; 112(4):1202-7. PubMed ID: 25583483 [TBL] [Abstract][Full Text] [Related]
15. Parkin ubiquitinates and promotes the degradation of RanBP2. Um JW; Min DS; Rhim H; Kim J; Paik SR; Chung KC J Biol Chem; 2006 Feb; 281(6):3595-603. PubMed ID: 16332688 [TBL] [Abstract][Full Text] [Related]
16. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. Winton MJ; Igaz LM; Wong MM; Kwong LK; Trojanowski JQ; Lee VM J Biol Chem; 2008 May; 283(19):13302-9. PubMed ID: 18305110 [TBL] [Abstract][Full Text] [Related]
17. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia. Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155 [TBL] [Abstract][Full Text] [Related]